title: Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs.
authors: Charlotte
authors: C
authors: Harrison
mesh_terms: D017326:Clinical Trials, Phase III as Topic; D000242:Cyclic AMP / Q000378:metabolism; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D016207:Cytokines / Q000378:metabolism; D017277:Drug Approval; D058988:Phosphodiesterase 4 Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D016207:Cytokines; D058988:Phosphodiesterase 4 Inhibitors; D013792:Thalidomide; D000242:Cyclic AMP; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C505730:apremilast